GM3(Neu5Gc) ganglioside: An evolution fixed neoantigen for cancer immunotherapy

Publication date: Available online 7 May 2018
Source:Seminars in Oncology
Author(s): Mayrel Labrada, Denise Dorvignit, Giselle Hevia, Nely Rodriguez, Ana M. Hernández, Ana M. Vázquez, Luis E. Fernández
Numerous molecules have been considered as target for cancer immunotherapy due to their levels of expression on tumor cells, their putative importance for tumor biology and relative immunogenicity. In this review we focused on the ganglioside GM3(Neu5Gc), a glycosphingolipid present on the outer side of plasma membranes of vertebrate cells. The reasons for selecting GM3(Neu5Gc) as a peculiar tumor specific antigen and its use as target for cancer immunotherapy are discussed, together with the development of antitumor therapies focused on this target by the Center of Molecular Immunology (CIM, Cuba).



https://ift.tt/2IWQ6KQ